查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1233089

神经病学临床试验市场规模,份额和趋势分析:按阶段(第一,第二),研究设计(介入),适应症,地区,市场预测,2022-2030

Neurology Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II), By Study Design (Interventional), By Indication, By Region, And Segment Forecasts, 2022 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

神经学临床试验市场增长和趋势

Grand View Research, Inc. 的一份新报告显示，2023 年至 2030 年，全球神经病学临床试验市场规模的年復合增长率将达到 5.6%，到 □□2030 年将达到 80 亿5290万美元。

这是由于各大製药公司在神经科学领域开展创新临床试验，增加政府对国家神经疾病和中风研究所 (NINDS) 的资助，以及全球范围内神经系统疾病的流行率高是主要原因。

神经科学继续获得稳健的投资。 例如，2022 年 11 月，NRG Therapeutics 宣布获得 1830 万美元的 A 轮融资，用于开发治疗肌萎缩侧索硬化症（ALS）和帕金森病等神经退行性疾□□病的线粒体疗法。 预计未来类似举措的采用将支持市场的增长。

在世界范围内，有相当多的人患有神经系统疾病。 例如，据帕金森基金会统计，每年有 6 万美国人被诊断患有帕金森病，全世界有超过 1000 万人患有这种疾病。 据世界卫生组织称，全世界有超过 6500 万人患有癫痫症。 该病在低收入和中等收入国家最为常见，占癫痫患者的80.0%。预计神经系统疾病的高患病率将推动对临床试验的需求并支持市场。

神经病学被认为是进行临床试验的主要领域之一。 根据医药研发年度回顾，2021年，神经病学试验将成为临床试验的第三大重点。 根据《医药研发年度回顾》，神经内科临床试验药物超过2900种，到2022年，神经内科临床试验活性药物将超过3200种。 进入神经病学临床试验的药物的增加预计将在大流行后时期支持市场。

神经病学临床试验市场报告要点。

  • 二期细分市场占据市场主导地位，在 2022 年占最大收入份额，达到 46.3%。 大多数神经病学临床试验目前处于支持该细分市场的第 2 阶段。
  • 到 2022 年，介入细分市场的收入份额最大，达到 96.1%。 使用这种试验设计类型进行的大量神经学临床试验正在推动这一细分市场的增长。
  • 亨廷顿氏舞蹈症领域预计在预测期内实现最快的复合年增长率 6.0%。 这主要是由于全世界对用于治疗亨廷顿舞蹈病的药物的需求量很大，因为没有可用于治疗它的药物。
  • 北美在市场中占据主导地位，2022 年占收入份额的 47.0%。 神经系统疾病患病率的上升和临床试验中众多参与者的出现正在推动该地区的市场。 这些是其高市场份额的一些主要原因。

内容

第 1 章调查方法及范围

  • 市场细分和范围
    • 阶段
    • 研究设计
    • 展示
    • 研究设计的适应症
    • 按阶段显示
  • 调查方法
  • 资讯采购
    • 购买的数据库
    • GVR 内部数据库
    • 次要资讯
    • 初步调查
    • 初步调查的内容
  • 资讯或数据分析
    • 数据分析模型
  • 市场製定和验证
  • 模型详细资讯
    • 商品流分析（模型1）
      • 方法 1：商品流方法
    • 批量价格分析（模型2）
      • 方法 2：体积分析
  • 二级资讯列表
  • 主要资讯列表
  • 目的

第 2 章执行摘要

  • 市场展望

第 3 章神经病学临床试验市场变量、趋势和范围

  • 市场系列展望
    • 母公司市场展望
    • 相关/子公司市场前景
  • 描绘采用情况和增长前景
  • 市场动态
    • 市场促进因素分析
      • 阿尔茨海默病、癫痫和中风等神经系统疾病的患病率增加
      • 在临床研究中更多地采用新技术
      • 许多提供神经病学临床研究服务的 CRO
      • 增加公共机构对神经学研究的资助
    • 市场抑制因素分析
      • 与神经学临床研究相关的高成本
      • 高失败率加上与神经临床试验相关的患者退出问题
  • 神经临床试验市场分析工具
    • 波特的五力分析
    • PEST分析
  • COVID-19 的影响和改革战略

第 4 章神经病学临床试验市场：阶段估计和趋势分析

  • 定义和范围
  • 神经临床试验市场：阶段市场份额分析，2022 年和 2030 年
    • 第一阶段
    • 第二阶段
    • 第三阶段
    • 第四阶段

第 5 章神经病学临床试验市场：研究设计估计和趋势分析

  • 定义和范围
  • 神经临床试验市场：研究设计市场份额分析，2022 年和 2030 年
    • 干预
    • 观察性的
    • 扩大访问范围

第 6 章神经病学临床试验市场：适应症估计和估计/趋势分析

  • 定义和范围
  • 神经临床试验市场：适应症市场份额分析，2022 年和 2030 年
    • 癫痫症
    • 帕金森病 (PD)
    • 亨廷顿舞蹈症
    • 中风
    • 创伤性脑损伤 (TBI)
    • 肌萎缩侧索硬化 (ALS)
    • 肌肉再生
    • 其他

第 7 章神经病学临床试验市场：研究设计估计和趋势分析的适应症

  • 定义和范围
  • 神经临床试验市场：按研究设计进行的适应症市场份额分析，2022 年和 2030 年
    • 癫痫症
      • 干预
      • 观察性的
      • 扩大访问范围
    • 帕金森病 (PD)
      • 干预
      • 观察性的
      • 扩大访问范围
    • 亨廷顿舞蹈症
      • 干预
      • 观察性的
      • 扩大访问范围
    • 中风
      • 干预
      • 观察性的
      • 扩大访问范围
    • 创伤性脑损伤 (TBI)
      • 干预
      • 观察性的
      • 扩大访问范围
    • 肌萎缩侧索硬化 (ALS)
      • 干预
      • 观察性的
      • 扩大访问范围
    • 肌肉再生
      • 干预
      • 观察性的
      • 扩大访问范围
    • 其他
      • 干预
      • 观察性的
      • 扩大访问范围

第 8 章神经病学临床试验市场：阶段估计和趋势分析的适应症

  • 定义和范围
  • 神经临床试验市场：分级适应症市场份额分析，2022 年和 2030 年
    • 癫痫症
      • 第一阶段
      • 第二阶段
      • 第三阶段
      • 第四阶段
    • 帕金森病 (PD)
      • 第一阶段
      • 第二阶段
      • 第三阶段
      • 第四阶段
    • 亨廷顿舞蹈症
      • 第一阶段
      • 第二阶段
      • 第三阶段
      • 第四阶段
    • 中风
      • 第一阶段
      • 第二阶段
      • 第三阶段
      • 第四阶段
    • 创伤性脑损伤 (TBI)
      • 第一阶段
      • 第二阶段
      • 第三阶段
      • 第四阶段
    • 肌萎缩侧索硬化 (ALS)
      • 第一阶段
      • 第二阶段
      • 第三阶段
      • 第四阶段
    • 肌肉再生
      • 第一阶段
      • 第二阶段
      • 第三阶段
      • 第四阶段
    • 其他
      • 第一阶段
      • 第二阶段
      • 第三阶段
      • 第四阶段

第 9 章神经病学临床试验市场：区域估计和趋势分析

  • 2022 年和 2030 年区域市场份额分析
  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 意大利
    • 西班牙
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
  • 多边环境协定
    • 南非
    • 沙特阿拉伯
    • 阿拉伯联合酋长国

第 10 章竞争格局

  • 市场份额分析
  • 参与公司
  • 近期发展和影响分析

第 11 章公司简介

  • 公司概况
  • 财务业绩
  • 战略举措
    • 分机
    • 伙伴关係和协作
    • 收购
      • Novartis
      • Covance
      • Med pace
      • Charles River Laboratories
      • Syneous Health
      • Icon Plc
      • GlaxoSmithKline
      • Aurora healthcare
      • Biogen
      • IQVIA
Product Code: GVR-4-68038-352-2

Neurology Clinical Trials Market Growth & Trends:

The global neurology clinical trials market size is expected to reach USD 8,052.9 million by 2030, registering a CAGR of 5.6% from 2023 to 2030, according to a new report by Grand View Research, Inc. This is largely attributed to big pharma companies conducting innovative trials in neurology, increased government funding from the National Institute of Neurological Disorders and Stroke (NINDS), and the high prevalence of neurological disorders worldwide.

Neuroscience continues to receive a healthy investment. For instance, in November 2022, NRG Therapeutics raised Series A funding of USD 18.3 million for the development of mitochondrial therapeutics to treat neurodegenerative ailments such as amyotrophic lateral sclerosis (ALS) and Parkinson's disease. The adoption of similar initiatives in the future is expected to support market growth.

A significant number of people worldwide suffer from neurological disorders. For instance, as per the statistics from Parkinson's Foundation, every year 60,000 Americans are diagnosed with PD and more than 10 million people are living with the disease around the world. In terms of Epilepsy, the WHO states that more than 65 million people worldwide are affected by it. The disease is most prevalent in low- and middle-income countries, which account for 80.0% of epilepsy cases. A high prevalence of neurological disorders is expected to boost demand for clinical trials and thus support the market.

Neurology is considered as one of the major areas where clinical trials are conducted. As per the Pharma R&D Annual Review, in 2021, Neurology trials were the third area where clinical trials were majorly focused. The Pharma R&D Annual Review stated that for neurology above 2,900 drugs were under trial and in the year 2022 the number of drugs for clinical studies in the area of neurology accounted for more than 3,200 active drugs. An increasing number of drugs entering clinical trials in the area of neurology are expected to support the market in the post-pandemic period.

Neurology Clinical Trials Market Report Highlights:

  • The phase II segment dominated the market and accounted for a maximum revenue share of 46.3% in 2022. A majority number of neurology clinical trials are currently in Phase 2, this is supporting the segment market
  • The interventional segment held the largest market revenue share of 96.1% in 2022. A high number of neurology clinical trials conducted through this study design type is promoting the growth of the segment market
  • The Huntington's disease segment is anticipated to register the fastest CAGR of 6.0% during the forecast period. This is largely due to the fact that there is a high demand for the medicines used for Huntington's disease worldwide as there are no medications available for treating this disease
  • North America dominated the market and accounted for a revenue share of 47.0% in 2022. The rising prevalence of neurological disorders and the presence of a large number of players in clinical trials drive the market in the region. These are some of the key reasons for the high market share

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Phase
    • 1.1.2. Study Design
    • 1.1.3. Indication
    • 1.1.4. Indication by Study Design
    • 1.1.5. Indication by Phase
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
      • 1.6.1.1. Approach 1: Commodity flow approach
    • 1.6.2. Volume price analysis (Model 2)
      • 1.6.2.1. Approach 2: Volume price analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook

Chapter 3. Neurology Clinical Trials Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & growth prospect mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
      • 3.3.1.1. Increasing prevalence of neurological diseases such as Alzheimer disease, epilepsy, and stroke
      • 3.3.1.2. Growing adoption of novel technologies in clinical research
      • 3.3.1.3. Significant number of CROs providing neurology clinical research services
      • 3.3.1.4. Increasing funding for neurological studies by public organizations
    • 3.3.2. Market restraint analysis
      • 3.3.2.1. High cost associated with neurology clinical studies.
      • 3.3.2.2. High failure rate coupled with patient dropout issues associated with neurological clinical trials.
  • 3.4. Neurology Clinical Trials Market Analysis Tools
    • 3.4.1. Porter's Five Forces Analysis
    • 3.4.2. PEST Analysis
  • 3.5. COVID-19 Impact and Reformation Strategy

Chapter 4. Neurology Clinical Trials Market: Phase Estimates & Trend Analysis

  • 4.1. Definitions and Scope
  • 4.2. Neurology Clinical Trials Market: Phase Market Share Analysis, 2022 & 2030
    • 4.2.1. Phase I
    • 4.2.2. Phase II
    • 4.2.3. Phase III
    • 4.2.4. Phase IV

Chapter 5. Neurology Clinical Trials Market: Study Design Estimates & Trend Analysis

  • 5.1. Definitions and Scope
  • 5.2. Neurology Clinical Trials Market: Study Design Market Share Analysis, 2022 & 2030
    • 5.2.1. Interventional
    • 5.2.2. Observational
    • 5.2.3. Expanded Access

Chapter 6. Neurology Clinical Trials Market: Indication Estimates & Trend Analysis

  • 6.1. Definitions and Scope
  • 6.2. Neurology Clinical Trials Market: Indication Market Share Analysis, 2022 & 2030
    • 6.2.1. Epilepsy
    • 6.2.2. Parkinson's Disease (PD)
    • 6.2.3. Huntington's Disease
    • 6.2.4. Stroke
    • 6.2.5. Traumatic Brain Injury (TBI)
    • 6.2.6. Amyotrophic Lateral Sclerosis (ALS)
    • 6.2.7. Muscle regeneration
    • 6.2.8. Others

Chapter 7. Neurology Clinical Trials Market: Indication By Study Design Estimates & Trend Analysis

  • 7.1. Definitions and Scope
  • 7.2. Neurology Clinical Trials Market: Indication By Study Design Market Share Analysis, 2022 & 2030
    • 7.2.1. Epilepsy
      • 7.2.1.1. Interventional
      • 7.2.1.2. Observational
      • 7.2.1.3. Expanded Access
    • 7.2.2. Parkinson's Disease (PD)
      • 7.2.2.1. Interventional
      • 7.2.2.2. Observational
      • 7.2.2.3. Expanded Access
    • 7.2.3. Huntington's Disease
      • 7.2.3.1. Interventional
      • 7.2.3.2. Observational
      • 7.2.3.3. Expanded Access
    • 7.2.4. Stroke
      • 7.2.4.1. Interventional
      • 7.2.4.2. Observational
      • 7.2.4.3. Expanded Access
    • 7.2.5. Traumatic Brain Injury (TBI)
      • 7.2.5.1. Interventional
      • 7.2.5.2. Observational
      • 7.2.5.3. Expanded Access
    • 7.2.6. Amyotrophic Lateral Sclerosis (ALS)
      • 7.2.6.1. Interventional
      • 7.2.6.2. Observational
      • 7.2.6.3. Expanded Access
    • 7.2.7. Muscle regeneration
      • 7.2.7.1. Interventional
      • 7.2.7.2. Observational
      • 7.2.7.3. Expanded Access
    • 7.2.8. Others
      • 7.2.8.1. Interventional
      • 7.2.8.2. Observational
      • 7.2.8.3. Expanded Access

Chapter 8. Neurology Clinical Trials Market: Indication By Phase Estimates & Trend Analysis

  • 8.1. Definitions and Scope
  • 8.2. Neurology Clinical Trials Market: Indication By Phase Market Share Analysis, 2022 & 2030
    • 8.2.1. Epilepsy
      • 8.2.1.1. Phase I
      • 8.2.1.2. Phase II
      • 8.2.1.3. Phase III
      • 8.2.1.4. Phase IV
    • 8.2.2. Parkinson's Disease (PD)
      • 8.2.2.1. Phase I
      • 8.2.2.2. Phase II
      • 8.2.2.3. Phase III
      • 8.2.2.4. Phase IV
    • 8.2.3. Huntington's Disease
      • 8.2.3.1. Phase I
      • 8.2.3.2. Phase II
      • 8.2.3.3. Phase III
      • 8.2.3.4. Phase IV
    • 8.2.4. Stroke
      • 8.2.4.1. Phase I
      • 8.2.4.2. Phase II
      • 8.2.4.3. Phase III
      • 8.2.4.4. Phase IV
    • 8.2.5. Traumatic Brain Injury (TBI)
      • 8.2.5.1. Phase I
      • 8.2.5.2. Phase II
      • 8.2.5.3. Phase III
      • 8.2.5.4. Phase IV
    • 8.2.6. Amyotrophic Lateral Sclerosis (ALS)
      • 8.2.6.1. Phase I
      • 8.2.6.2. Phase II
      • 8.2.6.3. Phase III
      • 8.2.6.4. Phase IV
    • 8.2.7. Muscle regeneration
      • 8.2.7.1. Phase I
      • 8.2.7.2. Phase II
      • 8.2.7.3. Phase III
      • 8.2.7.4. Phase IV
    • 8.2.8. Others
      • 8.2.8.1. Phase I
      • 8.2.8.2. Phase II
      • 8.2.8.3. Phase III
      • 8.2.8.4. Phase IV

Chapter 9. Neurology Clinical Trials Market: Regional Estimates & Trend Analysis

  • 9.1. Regional market share analysis, 2022 & 2030
  • 9.2. North America
    • 9.2.1. U.S.
      • 9.2.1.1. U.S. market estimates and forecast, 2018-2030
    • 9.2.2. Canada
      • 9.2.2.1. Canada market estimates and forecast, 2018-2030
  • 9.3. Europe
    • 9.3.1. U.K.
      • 9.3.1.1. U.K. market estimates and forecast, 2018-2030
    • 9.3.2. Germany
      • 9.3.2.1. Germany market estimates and forecast, 2018-2030
    • 9.3.3. France
      • 9.3.3.1. France market estimates and forecast, 2018-2030
    • 9.3.4. Italy
      • 9.3.4.1. Italy market estimates and forecast, 2018-2030
    • 9.3.5. Spain
      • 9.3.5.1. Spain market estimates and forecast, 2018-2030
  • 9.4. Asia Pacific
    • 9.4.1. Japan
      • 9.4.1.1. Japan market estimates and forecast, 2018-2030
    • 9.4.2. China
      • 9.4.2.1. China market estimates and forecast, 2018-2030
    • 9.4.3. India
      • 9.4.3.1. India market estimates and forecast, 2018-2030
    • 9.4.4. Australia
      • 9.4.4.1. Australia market estimates and forecast, 2018-2030
    • 9.4.5. South Korea
      • 9.4.5.1. South Korea market estimates and forecast, 2018-2030
  • 9.5. Latin America
    • 9.5.1. Brazil
      • 9.5.1.1. Brazil market estimates and forecast, 2018-2030
    • 9.5.2. Mexico
      • 9.5.2.1. Mexico market estimates and forecast, 2018-2030
    • 9.5.3. Argentina
      • 9.5.3.1. Argentina market estimates and forecast, 2018-2030
    • 9.5.4. Colombia
      • 9.5.4.1. Colombia market estimates and forecast, 2018-2030
  • 9.6. MEA
    • 9.6.1. South Africa
      • 9.6.1.1. South Africa market estimates and forecast, 2018-2030
    • 9.6.2. Saudi Arabia
      • 9.6.2.1. Saudi Arabia market estimates and forecast, 2018-2030
    • 9.6.3. UAE
      • 9.6.3.1. UAE market estimates and forecast, 2018-2030

Chapter 10. Competitive Landscape

  • 10.1. Market Share Analysis
  • 10.2. Participant Categorization
  • 10.3. Recent Development and Impact Analysis

Chapter 11. Company Profiles

  • 11.1. Company Overview
  • 11.2. Financial Performance
  • 11.3. Strategic Initiatives
    • 11.3.1. Expansions
    • 11.3.2. Partnerships and Collaborations
    • 11.3.3. Acquisitions
      • 11.3.3.1. Novartis
      • 11.3.3.2. Covance
      • 11.3.3.3. Med pace
      • 11.3.3.4. Charles River Laboratories
      • 11.3.3.5. Syneous Health
      • 11.3.3.6. Icon Plc
      • 11.3.3.7. GlaxoSmithKline
      • 11.3.3.8. Aurora healthcare
      • 11.3.3.9. Biogen
      • 11.3.3.10. IQVIA

List of Tables

  • TABLE 1 List of secondary sources
  • TABLE 2 List of Abbreviations

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information Procurement
  • FIG. 3 Primary research pattern
  • FIG. 4 Market research approaches
  • FIG. 5 Value chain based sizing & forecasting
  • FIG. 6 QFD modelling for market share assessment
  • FIG. 7 Market segmentation & scope
  • FIG. 8 Neurology Clinical Trials market outlook, 2018 - 2030
  • FIG. 9 Market trends & outlook
  • FIG. 10 Market driver relevance analysis (Current & future impact)
  • FIG. 11 Market restraint relevance analysis (Current & future impact)
  • FIG. 12 SWOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 13 Porter's Five Forces Analysis
  • FIG. 14 Neurology Clinical Trials market : Phase outlook key takeaways
  • FIG. 15 Neurology Clinical Trials market : Phase movement analysis
  • FIG. 16 Active Pharmaceutical Ingredients (API) market, 2018 - 2030 (USD Million)
  • FIG. 17 Phase I market, 2018 - 2030 (USD Million)
  • FIG. 18 Phase II market, 2018 - 2030 (USD Million)"
  • FIG. 19 Phase III market, 2018 - 2030"
  • FIG. 20 Phase IV market, 2018 - 2030 (USD Million)
  • FIG. 21 Neurology Clinical Trials market : Indication outlook key takeaways
  • FIG. 22 Neurology Clinical Trials market : Indication movement analysis
  • FIG. 23 Epilepsy market, 2018 - 2030
  • FIG. 24 Parkinson's Disease (PD) market, 2018 - 2030 (USD Million)
  • FIG. 25 Huntington's Disease market, 2018 - 2030 (USD Million)
  • FIG. 26 Stroke market, 2018 - 2030 (USD Million)
  • FIG. 27 Traumatic Brain Injury (TBI) market, 2018 - 2030 (USD Million)
  • FIG. 28 Stroke market, 2018 - 2030 (USD Million)
  • FIG. 29 Amyotrophic Lateral Sclerosis (ALS) market, 2018 - 2030 (USD Million)
  • FIG. 30 Muscle regeneration market, 2018 - 2030 (USD Million)
  • FIG. 31 Others market, 2018 - 2030 (USD Million)
  • FIG. 32 Neurology Clinical Trials market: Study Design outlook key takeaways
  • FIG. 33 Neurology Clinical Trials market: Study Design movement analysis
  • FIG. 34 Interventional market, 2018 - 2030 (USD Million)
  • FIG. 35 Observational market, 2018 - 2030 (USD Million)
  • FIG. 36 Expanded Access, 2018 - 2030 (USD Million)
  • FIG. 37 Neurology Clinical Trials market: Indication by Study Design outlook key takeaways
  • FIG. 38 Neurology Clinical Trials market: Indication by Study Design movement analysis
  • FIG. 39 Epilepsy interventional studies market, 2018 - 2030 (USD Million)
  • FIG. 40 Epilepsy observational studies market, 2018 - 2030 (USD Million)
  • FIG. 41 Epilepsy expanded acess studies market, 2018 - 2030 (USD Million)
  • FIG. 42 Parkinson's Disease (PD) interventional studies market, 2018 - 2030 (USD Million)
  • FIG. 43 Parkinson's Disease (PD) observational studies market, 2018 - 2030 (USD Million)
  • FIG. 44 Parkinson's Disease (PD) expanded acess studies market, 2018 - 2030 (USD Million)
  • FIG. 45 Huntington's Disease interventional studies market, 2018 - 2030 (USD Million)
  • FIG. 46 Huntington's Diseaseobservational studies market, 2018 - 2030 (USD Million)
  • FIG. 47 Huntington's Disease expanded acess studies market, 2018 - 2030 (USD Million)
  • FIG. 48 Stroke interventional studies market, 2018 - 2030 (USD Million)
  • FIG. 49 Stroke observational studies market, 2018 - 2030 (USD Million)
  • FIG. 50 Stroke expanded acess studies market, 2018 - 2030 (USD Million)
  • FIG. 51 Traumatic Brain Injury (TBI) interventional studies market, 2018 - 2030 (USD Million)
  • FIG. 52 Traumatic Brain Injury (TBI) observational studies market, 2018 - 2030 (USD Million)
  • FIG. 53 Traumatic Brain Injury (TBI) expanded acess studies market, 2018 - 2030 (USD Million)
  • FIG. 54 Amyotrophic Lateral Sclerosis (ALS) interventional studies market, 2018 - 2030 (USD Million)
  • FIG. 55 Amyotrophic Lateral Sclerosis (ALS) observational studies market, 2018 - 2030 (USD Million)
  • FIG. 56 Amyotrophic Lateral Sclerosis (ALS) expanded acess studies market, 2018 - 2030 (USD Million)
  • FIG. 57 Muscle regeneration interventional studies market, 2018 - 2030 (USD Million)
  • FIG. 58 Muscle regeneration observational studies market, 2018 - 2030 (USD Million)
  • FIG. 59 Muscle regeneration expanded acess studies market, 2018 - 2030 (USD Million)
  • FIG. 60 Others interventional studies market, 2018 - 2030 (USD Million)
  • FIG. 61 Others observational studies market, 2018 - 2030 (USD Million)
  • FIG. 62 Others expanded acess studies market, 2018 - 2030 (USD Million)
  • FIG. 63 Neurology Clinical Trials market: Indication by Phase outlook key takeaways
  • FIG. 64 Neurology Clinical Trials market: Indication by Phase movement analysis
  • FIG. 65 "Epilepsy Phase I market, 2018 - 2030 (USD Million)"
  • FIG. 66 Epilepsy Phase II market, 2018 - 2030 (USD Million)
  • FIG. 67 Epilepsy Phase III market, 2018 - 2030 (USD Million)
  • FIG. 68 Epilepsy Phase IV market, 2018 - 2030 (USD Million)
  • FIG. 69 Parkinson's Disease (PD) Phase I market, 2018 - 2030 (USD Million)
  • FIG. 70 Parkinson's Disease (PD) Phase II market, 2018 - 2030 (USD Million)
  • FIG. 71 Parkinson's Disease (PD) Phase III market, 2018 - 2030 (USD Million)
  • FIG. 72 Parkinson's Disease (PD) Phase IV market, 2018 - 2030 (USD Million)
  • FIG. 73 Huntington's Disease Phase I market, 2018 - 2030 (USD Million)
  • FIG. 74 Huntington's Disease Phase II market, 2018 - 2030 (USD Million)
  • FIG. 75 Huntington's Disease Phase III market, 2018 - 2030 (USD Million)
  • FIG. 76 Huntington's Disease Phase IV market, 2018 - 2030 (USD Million)
  • FIG. 77 Stroke Phase I market, 2018 - 2030 (USD Million)
  • FIG. 78 Stroke Phase II market, 2018 - 2030 (USD Million)
  • FIG. 79 Stroke Phase III market, 2018 - 2030 (USD Million)
  • FIG. 80 Stroke Phase IV market, 2018 - 2030 (USD Million)
  • FIG. 81 Traumatic Brain Injury (TBI) Phase I market, 2018 - 2030 (USD Million)
  • FIG. 82 Traumatic Brain Injury (TBI) Phase II market, 2018 - 2030 (USD Million)
  • FIG. 83 Traumatic Brain Injury (TBI) Phase III market, 2018 - 2030 (USD Million)
  • FIG. 84 Traumatic Brain Injury (TBI) Phase IV market, 2018 - 2030 (USD Million)
  • FIG. 85 Amyotrophic Lateral Sclerosis (ALS)Phase I market, 2018 - 2030 (USD Million)
  • FIG. 86 Amyotrophic Lateral Sclerosis (ALS) Phase II market, 2018 - 2030 (USD Million)
  • FIG. 87 Amyotrophic Lateral Sclerosis (ALS) Phase III market, 2018 - 2030 (USD Million)
  • FIG. 88 Amyotrophic Lateral Sclerosis (ALS) Phase IV market, 2018 - 2030 (USD Million)
  • FIG. 89 Muscle regeneration Phase I market, 2018 - 2030 (USD Million)
  • FIG. 90 Muscle regeneration Phase II market, 2018 - 2030 (USD Million)
  • FIG. 91 Muscle regeneration Phase III market, 2018 - 2030 (USD Million)
  • FIG. 92 Muscle regeneration Phase IV market, 2018 - 2030 (USD Million)
  • FIG. 93 Others Phase I market, 2018 - 2030 (USD Million)
  • FIG. 94 Others Phase II market, 2018 - 2030 (USD Million)
  • FIG. 95 Others Phase III market, 2018 - 2030 (USD Million)
  • FIG. 96 Others Phase IV market, 2018 - 2030 (USD Million)
  • FIG. 97 Regional market place: Key takeaway
  • FIG. 98 Neurology Clinical Trials regional outlook, 2020 & 2028
  • FIG. 99 North America Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 100 U.S. Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 101 Canada Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 102 Europe Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 103 Germany Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 104 France Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 105 U.K. Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 106 Spain Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 107 Italy Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 108 Asia Pacific Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 109 Japan Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 110 India Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 111 China Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 112 South Korea Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 113 Australia Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 114 Latin America Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 115 Brazil Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 116 Mexico Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 117 Argentina Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 118 Colombia Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 119 Middle East & Africa Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 120 South Africa Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 121 Saudi Arabia Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 122 UAE Neurology Clinical Trials market, 2018 - 2030 (USD Million)